• Customer receipts declined 26% on PCP, reflecting softer market conditions and increased competition in China
• Operating cash outflow of $2.2 million, primarily due to significant tax payments and increased advertising spend
• Continued expansion of domestic pharmacy network with 10 new stores and industry award recognition

EZZ Life Science Holdings Ltd (ASX: EZZ) has released its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2025 (Q2 FY26). Key highlights include:- Customer receipts increased modestly over Q1 FY26 but declined 26% on the prior corresponding period, reflecting softer market conditions and increased competition in China.- Operating cash outflow of $2.2 million, primarily reflecting significant tax payments made during the quarter and increased advertising spend ahead of the 2026 Australian Open.- Continued expansion of the domestic pharmacy network with 10 new stores, including one Priceline Pharmacy and nine Direct Chemist Outlet locations.- Received the 21st Century 'Sunshine Evaluation' Enterprise Award, acknowledging the company's commitment to quality, market-responsive innovation, and consumer-centric product development.- Appointment of former Chair Glenn Cross as Chief Strategy Officer to lead U.S. market expansion initiatives.- Final FY25 dividend of $0.89 million paid in accordance with the company's dividend policy.- Cash and cash equivalents of $13.5 million at 31 December 2025, with the company remaining debt free (excluding lease liabilities).The company remains focused on executing its global growth strategy through continued product innovation, disciplined market expansion, and the strengthening of local retail and distribution partnerships. Key priorities for the remainder of FY26 include advancing product development, scaling presence in selected international markets, deepening domestic and offshore retail relationships, and enhancing brand visibility through targeted events and strategic collaborations.

EZZ remains focused on executing its global growth strategy through continued product innovation, disciplined market expansion and the strengthening of local retail and distribution partnerships. Key priorities for the remainder of FY26 include advancing product development aligned with regional wellness trends, scaling presence in selected international markets, deepening domestic and offshore retail relationships and enhancing brand visibility through targeted events and strategic collaborations.